Arbutus Biopharma (ABUS) Free Cash Flow (2013 - 2026)

Arbutus Biopharma (ABUS) has reported Free Cash Flow for 14 consecutive years, with -$8.1 million the latest figure, recorded in Q1 2026.

• Quarterly Free Cash Flow rose 39.44% year-over-year to -$8.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$34.4 million (up 41.8% YoY) and the FY2025 annual result came in at -$39.6 million, up 39.05% from the prior year.
• Free Cash Flow retreated to -$8.1 million in Q1 2026 per ABUS's latest filing, from -$4.7 million in the prior quarter.
• Over the last five years, Free Cash Flow for ABUS reached as high as $20.5 million in Q1 2022 and fell as low as -$27.4 million in Q1 2023.
• A 5-year average of -$13.9 million and a median of -$17.1 million in 2022 frame the typical range for Free Cash Flow.
• Annual changes were most pronounced in 2022 — Free Cash Flow jumped 214.26% — and 2023, when it tumbled 233.46%.
• Year by year, Free Cash Flow stood at -$17.1 million in 2022, then retreated by 0.98% to -$17.3 million in 2023, then soared by 39.85% to -$10.4 million in 2024, then surged by 55.0% to -$4.7 million in 2025, then tumbled by 73.29% to -$8.1 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$8.1 million, -$4.7 million, and -$5.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.